文献速递临床试验与 GCP基础与转化研究

苏金单抗治疗巨细胞动脉炎:随机双盲安慰剂对照II期试验方案

Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial.
PubMed 文献 · Trials · 2021-08-17

BACKGROUND: One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries.…

要点

  • 苏金单抗300mg皮下注射联合26周泼尼松龙减量方案用于巨细胞动脉炎。
  • 主要终点为第28周持续缓解比例,采用贝叶斯方法比较组间差异。
  • 设两个可选影像学子研究评估血管壁炎症和闭塞变化。

核心结论

  • 该试验设计旨在首次提供苏金单抗治疗巨细胞动脉炎的安慰剂对照疗效和安全性数据。

研究设计与样本

  • 随机、平行组、双盲、安慰剂对照、多中心II期研究,患者、治疗医生、相关临床人员及申办方临床团队均设盲。

关键数值与推荐

  • 苏金单抗组予300mg皮下注射,基线、第1、2、3周及第4周起每4周给药;两组均接受26周泼尼松龙减量方案。
  • 主要终点为第28周持续缓解的患者比例,采用贝叶斯方法分析。
  • 第12周未达到缓解、缓解后复发或无法坚持泼尼松龙减量的患者进入逃逸臂,按研究者临床判断给予泼尼松龙并继续盲法治疗。
  • 研究包括最长6周筛选期、52周治疗期(含26周减量)和8周安全性随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: One key pathological finding in giant cell arteritis (GCA) is the presence of interferon-gamma and interleukin (IL)-17 producing T helper (Th) 1 and Th17 cells in affected arteries. There is anecdotal evidence of successful induction and maintenance of remission with the monoclonal anti-IL-17A antibody secukinumab. Inhibition of IL-17A could therefore represent a potential new therapeutic option for the treatment of GCA. METHODS: This is a randomized, parallel-group, double-blind, placebo-controlled, multi-center, phase II study in which patients, treating physicians, and the associated clinical staff as well as the sponsor clinical team are blinded. It is designed to evaluate efficacy and safety of secukinumab compared to placebo in combination with an open-label prednisolone taper regimen. Patients included are naïve to biological therapy and have newly diagnosed or relapsing GCA. Fifty patients are randomly assigned in a 1:1 ratio to receive either 300 mg secukinumab or placebo subcutaneously at baseline, weeks 1, 2 and 3, and every 4 weeks from week 4. Patients in both treatment arms receive a 26-week prednisolone taper regimen. The study consists of a maximum 6-week screening period, a 52-week treatment period (including the 26-week tapering), and an 8-week safety follow-up, with primary and secondary endpoint assessments at week 28. Patients who do not achieve remission by week 12 experience a flare after remission or cannot adhere to the prednisolone tapering will enter the escape arm and receive prednisolone at a dose determined by the investigator's clinical judgment. The blinded treatment is continued. Two optional imaging sub-studies are included (ultrasound and contrast-media enhanced magnetic resonance angiography [MRA]) to assess vessel wall inflammation and occlusion before and after treatment. The primary endpoint is the proportion of patients in sustained remission until week 28 in the secukinumab group compared to the proportion of patients in the placebo group. A Bayesian approach is applied. DISCUSSION: The trial design allows the first placebo-controlled data collection on the efficacy and safety of secukinumab in patients with GCA. TRIAL REGISTRATION: ClinicalTrials.gov NCT03765788 . Registration on 5 December 2018, prospective registration, EudraCT number 2018-002610-12; clinical trial protocol number CAIN457ADE11C.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Venhoff N, Schmidt WA, Lamprecht P, et al. Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial. Trials. 2021. PMID: 34404463. doi:10.1186/s13063-021-05520-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。